<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-11-15720</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0029513</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Proteins</subject>
              <subj-group>
                <subject>Protein chemistry</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Biophysics</subject>
            <subj-group>
              <subject>Protein chemistry</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Gene expression</subject>
              <subj-group>
                <subject>Protein translation</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Molecular cell biology</subject>
            <subj-group>
              <subject>Gene expression</subject>
              <subj-group>
                <subject>Protein translation</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Signal transduction</subject>
              <subj-group>
                <subject>Signaling in cellular processes</subject>
                <subj-group>
                  <subject>Tor signaling</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Complementary and alternative medicine</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Physics</subject>
          <subj-group>
            <subject>Biophysics</subject>
            <subj-group>
              <subject>Protein chemistry</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Genetics and Genomics</subject>
          <subject>Molecular Biology</subject>
          <subject>Biophysics</subject>
          <subject>Physics</subject>
          <subject>Biochemistry</subject>
        </subj-group>
      </article-categories><title-group><article-title>Resveratrol Inhibits Protein Translation in Hepatic Cells</article-title><alt-title alt-title-type="running-head">Resveratrol Modulates Protein Translation</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Villa-Cuesta</surname>
            <given-names>Eugenia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Boylan</surname>
            <given-names>Joan M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Tatar</surname>
            <given-names>Marc</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gruppuso</surname>
            <given-names>Philip A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Ecology and Evolutionary Biology, Brown University, Providence, Rhode Island, United States of America</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Pediatrics, Brown University and Rhode Island Hospital, Providence, Rhode Island, United States of America</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Bozza</surname>
            <given-names>Patricia T.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Fundação Oswaldo Cruz, Brazil</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">Eugenia_Villa-Cuesta@brown.edu</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: EV-C JMB PAG. Performed the experiments: EV-C JMB. Analyzed the data: EV-C PAG. Wrote the paper: EV-C PAG MT.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>29</day>
        <month>12</month>
        <year>2011</year>
      </pub-date><volume>6</volume><issue>12</issue><elocation-id>e29513</elocation-id><history>
        <date date-type="received">
          <day>10</day>
          <month>8</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>11</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Villa-Cuesta et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Resveratrol is a plant-derived polyphenol that extends lifespan and healthspan in model organism. Despite extensive investigation, the biological processes mediating resveratrol's effects have yet to be elucidated. Because repression of translation shares many of resveratrol's beneficial effects, we hypothesized that resveratrol was a modulator of protein synthesis. We studied the effect of the drug on the H4-II-E rat hepatoma cell line. Initial studies showed that resveratrol inhibited global protein synthesis. Given the role of the mammalian Target of Rapamycin (mTOR) in regulating protein synthesis, we examined the effect of resveratrol on mTOR signaling. Resveratrol inhibited mTOR self-phosphorylation and the phosphorylation of mTOR targets S6K1 and eIF4E-BP1. It attenuated the formation of the translation initiation complex eIF4F and increased the phosphorylation of eIF2α. The latter event, also a mechanism for translation inhibition, was not recapitulated by mTOR inhibitors. The effects on mTOR signaling were independent of effects on AMP-activated kinase or AKT. We conclude that resveratrol is an inhibitor of global protein synthesis, and that this effect is mediated through modulation of mTOR-dependent and independent signaling.</p>
      </abstract><funding-group><funding-statement>This work is supported by National Institutes of Health grant R01HD24455 (to P.A.G.), R01AG024360 (to M.T.) and American Parkinson Disease Association grant 529302 (to M.T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="10"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Resveratrol is a plant-derived polyphenol found in grapes, red wine, and other foods. This compound extends the lifespan of lower organisms (yeast, worms, flies and fish) <xref ref-type="bibr" rid="pone.0029513-Howitz1">[1]</xref>–<xref ref-type="bibr" rid="pone.0029513-Valenzano1">[3]</xref> and protects rodents from a variety of age-related diseases, including cancer, cardiovascular disease, obesity and diabetes <xref ref-type="bibr" rid="pone.0029513-Jang1">[4]</xref>–<xref ref-type="bibr" rid="pone.0029513-Baur2">[8]</xref>. Resveratrol is considered a mimetic for some of the beneficial effects of caloric restriction (reduction of food intake without malnutrition), which is the only environmental intervention known to extend longevity in a wide range of organisms <xref ref-type="bibr" rid="pone.0029513-Bishop1">[9]</xref>, <xref ref-type="bibr" rid="pone.0029513-Mair1">[10]</xref>.</p>
      <p>A relationship between extended longevity and decreased translation has been observed in a variety of conditions, including caloric restriction <xref ref-type="bibr" rid="pone.0029513-Hansen1">[11]</xref>, <xref ref-type="bibr" rid="pone.0029513-Zid1">[12]</xref> and inhibition of the nutrient–sensing kinase termed mTOR (<underline>m</underline>ammalian <underline>T</underline>arget <underline>o</underline>f <underline>R</underline>apamycin) <xref ref-type="bibr" rid="pone.0029513-Hansen1">[11]</xref>, <xref ref-type="bibr" rid="pone.0029513-Vellai1">[13]</xref>–<xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>. In fact, recent studies have shown that continuous administration of rapamycin, a specific inhibitor of mTOR Complex 1 (mTORC1), increases lifespan in mice <xref ref-type="bibr" rid="pone.0029513-Harrison1">[19]</xref> and flies <xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>. mTORC1 is one of the two complexes, the other being mTORC2, that account for signaling via mTOR. mTORC1 responds to growth factors, cellular energy and nutrient status by stimulating, among other processes, the initiation of mRNA translation <xref ref-type="bibr" rid="pone.0029513-Ma1">[20]</xref>. This involves mTORC1-mediated phosphorylation of the eukaryotic initiation factor 4E-binding protein 1 (eIF4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). Phosphorylation of eIF4E-BP1 leads to its release from the cap-binding factor eIF4E, thereby upregulating cap-dependent translation <xref ref-type="bibr" rid="pone.0029513-Richter1">[21]</xref>. Loss of function of eIF4E-BP or S6K1 retards the aging process in flies and mice <xref ref-type="bibr" rid="pone.0029513-Zid1">[12]</xref>, <xref ref-type="bibr" rid="pone.0029513-Selman1">[17]</xref>, <xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>, suggesting that attenuation of signaling through a single mTOR target is sufficient to extend longevity.</p>
      <p>mTOR signaling can be activated in response to the serine-threonine kinase AKT. In response to insulin, phosphatidylinositol-3 kinase (PI3K) is activated, leading to the activation of phosphoinositide-dependent kinase-1 (PDK-1), which in turn phosphorylates AKT at Thr 308. Resulting activation of AKT inhibits the formation of the tuberous sclerosis comple/2 (TSC) and de-represses mTORC1 activity <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>. Conversely, low cellular energy levels suppress mTORC1 activity via activation of AMP-activated kinase α (AMPKα). AMPKα activation mediates TSC2 phosphorylation, which results in down regulation of mTORC1 activity <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>. In addition, AMPKα is also able to directly phosphorylate the mTORC1 binding partner Raptor <xref ref-type="bibr" rid="pone.0029513-Gwinn1">[23]</xref>. Interestingly, metformin, an activator of AMPK signaling <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>, has been shown to increase longevity and decelerate cancer formation in mice <xref ref-type="bibr" rid="pone.0029513-Anisimov1">[24]</xref>, <xref ref-type="bibr" rid="pone.0029513-Anisimov2">[25]</xref>.</p>
      <p>Among the human disorders that involve dysregulation of mTOR signaling is cancer. Until recently, rapamycin was the only known mTOR inhibitor. However, the acquired resistance of many tumors to rapamycin prompted studies that led to the recent discovery of other mTOR inhibitors <xref ref-type="bibr" rid="pone.0029513-Guertin1">[26]</xref>, including Torin1 and pp242. These inhibitors target the mTOR kinase itself, thereby blocking signal transduction by both mTORC1 and mTORC2.</p>
      <p>Until now, the effects of resveratrol and mTOR signaling on longevity and cancer have been considered independent, although mTOR signaling has been shown to be involved in both <xref ref-type="bibr" rid="pone.0029513-Hansen1">[11]</xref>, <xref ref-type="bibr" rid="pone.0029513-Vellai1">[13]</xref>–<xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>, <xref ref-type="bibr" rid="pone.0029513-Guertin2">[27]</xref>–<xref ref-type="bibr" rid="pone.0029513-Kaeberlein2">[31]</xref>. In the present studies, we examined the effect of resveratrol on the control of protein synthesis and the activation of mTORC1 targets in rat hepatoma cells. Our results show that resveratrol can inhibit global translation in association with signaling effects that are both mTORC1-dependent and independent, thus providing a potential link between control of protein synthesis and the salutary effects of resveratrol on aging and related disease states.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Resveratrol inhibits protein translation in rat hepatoma cells</title>
        <p>High concentrations of resveratrol can induce lysis of human hepatic cells <xref ref-type="bibr" rid="pone.0029513-Delmas1">[32]</xref>. To avoid such toxicity as a confounding factor, we first determined the maximum resveratrol concentration at which viability of the H4-II-E cells was maintained. Concentrations of resveratrol ranging from 0.01 µM to 500 µM were examined for effects on cell viability. Concentrations up to 5 µM were not associated with changes in cell adherence or morphology. Higher concentrations caused cells to round up and release from the surface of the cell culture plate. Through the use of cell counts and the vital dye trypan blue, we confirmed that 5 µM resveratrol was not associated with reduced cell proliferation or cell viability (<xref ref-type="fig" rid="pone-0029513-g001">Figure 1A</xref>).</p>
        <fig id="pone-0029513-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Effect of resveratrol on cell proliferation, viability, and protein synthesis.</title>
            <p><italic>Panel A</italic>: H4-II-E hepatoma cells were incubated with DMSO vehicle (control), or resveratrol for 6 hr, at the end of which time total cell number and percentage of dead cells were determined by trypan blue staining and counting. <italic>Panel B</italic>: Cells were incubated with DMSO vehicle (control; filled circles), or resveratrol (unfilled circles) and <sup>14</sup>C-Leu for 0, 2, 4 or 6 h. At the end of these incubation periods, cell lysates were prepared and analyzed for radiolabeled leucine incorporation into protein. Data, shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA. <italic>Panel C</italic>: <sup>3</sup>H-Leu incorporation was similarly determined after a 6 h incubation period. <xref ref-type="sec" rid="s2">Results</xref>, normalized to DNA content, are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g001" xlink:type="simple"/>
        </fig>
        <p>To determine the effect of resveratrol on protein synthesis, we measured the incorporation of radiolabeled leucine into protein over a time course ranging from 0 to 6 h. <sup>14</sup>C-Leu incorporation was significantly decreased after cells were treated with 5 µM resveratrol for 4 and 6 h with the value at 2 h not quite reaching statistical significance (<xref ref-type="fig" rid="pone-0029513-g001">Figure 1B</xref>). This was interpreted as evidence for a consistent effect of resveratrol on protein synthesis that increased in magnitude with increased duration of exposure. In a repeat experiment in which cells were incubated for 6 h with <sup>3</sup>H-Leu and resveratrol, protein synthesis was inhibited by approximately 50% when normalized for DNA content (<xref ref-type="fig" rid="pone-0029513-g001">Figure 1C</xref>). DNA content was not significantly affected by resveratrol.</p>
        <p>One potential caveat in the interpretation of global protein synthesis measurements would be an effect of resveratrol on the transport of leucine into the cell. To test this, cells were exposed to resveratrol for 1 h prior to incubation with <sup>3</sup>H-Leu for 5, 10 and 15 minutes. At these short time points, <sup>3</sup>H-Leu incorporation into protein is minimal. In two experiments, cell content of <sup>3</sup>H-Leu was not significantly affected by resveratrol (<xref ref-type="supplementary-material" rid="pone.0029513.s001">Figure S1A</xref>), indicating the absence of an effect on leucine transport. In a separate experiment, cells were incubated with <sup>3</sup>H-Leu for 24 h. The media was removed, the cells were washed, and resveratrol or vehicle was added. <sup>3</sup>H-Leu remaining in protein was determined after 6 h. <xref ref-type="sec" rid="s2">Results</xref> showed that resveratrol did not affect protein degradation (<xref ref-type="supplementary-material" rid="pone.0029513.s001">Figure S1B</xref>).</p>
      </sec>
      <sec id="s2b">
        <title>Resveratrol inhibits mTOR-mediated phosphorylation events</title>
        <p>Having determined that resveratrol inhibits protein synthesis in H4-II-E cells, and given the central role of mTOR in translation control, we went on to examine the effect of resveratrol on mTOR signaling. Cells were treated with resveratrol, rapamycin, a specific inhibitor of mTORC1, or pp242, an inhibitor of mTOR kinase activity <xref ref-type="bibr" rid="pone.0029513-Guertin1">[26]</xref>. Cells were lysed after 1 h. Extracts were analyzed by Western immunoblotting.</p>
        <p>Resveratrol, rapamycin and pp242 all decreased the phosphorylation of mTOR at a known self-phosphorylation site, Ser 2481 (<xref ref-type="fig" rid="pone-0029513-g002">Figure 2A</xref>). Similarly, phosphorylation of S6K1 at an mTOR-dependent site (Thr 389 in the human protein), was inhibited by all three agents (<xref ref-type="fig" rid="pone-0029513-g002">Figure 2B</xref>). Phosphorylation of 4E-BP1 at mTOR-dependent sites (Thr 37/46) was reduced significantly, though less markedly, by resveratrol, rapamycin and pp242 treatment (<xref ref-type="fig" rid="pone-0029513-g002">Figure 2C</xref>).</p>
        <fig id="pone-0029513-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Effect of resveratrol and mTOR inhibitors on mTOR-mediated phosphorylation.</title>
            <p>H4-II-E hepatoma cells were incubated with DMSO vehicle (control), resveratrol, rapamycin or pp242 for 1 h. Cell lysates were prepared and analyzed by Western immunoblotting. The results of triplicate immunoblots were quantified by densitometry. Data were normalized between blots by analyzing a single control sample on all blots. The results shown in the graphs represent the ratio of phospho∶total mTOR (<italic>Panel A</italic>), S6K1 (<italic>Panel B</italic>) and eIF4E-BP1 (<italic>Panel C</italic>). Representative immunoblots are shown below each graph. <xref ref-type="sec" rid="s2">Results</xref> are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g002" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2c">
        <title>Resveratrol decreases eIF4F complex formation</title>
        <p>Initiation of mRNA translation, the primary determinant of translation efficiency, requires the assembling of eukaryotic initiation factors (eIFs) into the multiprotein complex eIF4F. eIF4F includes the cap-recognition factor eIF4E and the scaffold protein eIF4G <xref ref-type="bibr" rid="pone.0029513-Sonenberg1">[33]</xref>. To determine if resveratrol affects the formation of the eIF4F complex, cells were incubated with resveratrol, rapamycin or pp242 for 1 h. Cell lysates were subjected to 7mGTP affinity purification of the eIF4F complex. Resveratrol decreased the amount of eIF4G bound to eIF4E (<xref ref-type="fig" rid="pone-0029513-g003">Figure 3</xref>). This decrease was similar in magnitude to that observed in cells incubated with rapamycin but less than that resulting from exposure to pp242.</p>
        <fig id="pone-0029513-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>The effect of resveratrol and mTOR inhibitors on the formation of the eIF4F translation initiation translation complex.</title>
            <p>H4-II-E hepatoma cells were incubated with vehicle (control), resveratrol, rapamycin or pp242 for 1 h. eIF4E-containing complexes were purified from cell lysates using 7mGTP-Sepharose beads. The affinity purified proteins were analyzed by Western immunoblotting using antibodies against eIF4E and eIF4G. Representative immunoblots are shown above the graph. The immunoblots were quantified by densitometry to obtain a ratio of eIF4G to eIF4E for each condition. In order to compare results across experiments, results were expressed as percent of control for each individual experiment and are shown as the mean and standard error of the mean for triplicate determinations.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g003" xlink:type="simple"/>
        </fig>
        <p>We also examined the phosphorylation of eIF4G1 in the affinity purified eIF4F complexes. Resveratrol exposure was associated with a modest decrease in phosphorylation at Ser 1108, a site that has been shown to be mTORC1-dependent <xref ref-type="bibr" rid="pone.0029513-Raught1">[34]</xref> (data not shown).</p>
      </sec>
      <sec id="s2d">
        <title>Resveratrol–mediated inhibition of mTOR signaling cannot be attributed to effects on AMPK and AKT signaling</title>
        <p>Signaling through mTORC1 is modulated in response to upstream signaling involving AMPK and AKT <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>. To assess the effect of resveratrol on these upstream kinases, cell lysates prepared from H4-II-E cells treated with resveratrol were analyzed by Western immunoblotting.</p>
        <p>We first examined AMPKα (<xref ref-type="fig" rid="pone-0029513-g004">Figure 4A</xref>). Using the serum-containing media that were employed for our experiments, phosphorylation of AMPKα was not affected significantly by 0.5 mM of aminoimidazole carboxamide ribonucleotide (AICAR), an AMPKα agonist. Although higher concentrations of AICAR decreased cell viability (data not shown), phosphorylation of AMPKα could be induced by exposure to 0.5 mM of AICAR under serum-free conditions without evidence of cell toxicity, as previously reported <xref ref-type="bibr" rid="pone.0029513-Corton1">[35]</xref>. In neither condition was phosphorylation of AMPKα at Thr172 increased in response to resveratrol. Furthermore, resveratrol did not significantly increase phosphorylation of acetyl-CoA carboxylase, a marker of AMPKα signaling (<xref ref-type="fig" rid="pone-0029513-g004">Figure 4B</xref>).</p>
        <fig id="pone-0029513-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>The effect of resveratrol on AMPK activation.</title>
            <p><italic>Panel A</italic>: H4-II-E hepatoma cells were incubated with DMSO vehicle (control), resveratrol or AICAR for 1 h in serum containing media (<italic>left</italic>) or serum free media (<italic>right</italic>). Cell lysates were analyzed by immunoblotting for total and phosphorylated AMPKα. <italic>Panel B</italic>: Cells were incubated with DMSO vehicle (control) or resveratrol for 1 h. Samples were analyzed for acetyl CoA carboxylase (ACC) phosphorylation and content. The positions of the α and β ACC isoforms are shown to the right of representative immunoblots. For both panels, the results of triplicate immunoblots were quantified by densitometry. <xref ref-type="sec" rid="s2">Results</xref> are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g004" xlink:type="simple"/>
        </fig>
        <p>We went on to study signaling involving AKT (<xref ref-type="fig" rid="pone-0029513-g005">Figure 5</xref>). Under basal conditions, AKT phosphorylation at the PDK1-dependent Thr308 site was minimal. This was particularly apparent when contrasted with results obtained with cells exposed to 100 nM of insulin for 5 min. The low level of AKT phosphorylation under basal conditions precluded the detection of an inhibitory effect of resveratrol. To determine if resveratrol inhibits the phosphorylation of AKT at Thr308 upon insulin stimulation, we incubated cells with resveratrol or the PI3K inhibitor LY294002 as a control <xref ref-type="bibr" rid="pone.0029513-Vlahos1">[36]</xref>. Insulin-induced phosphorylation of AKT at Thr308 was not reduced significantly by resveratrol. As expected, LY294002 blocked insulin-induced AKT Thr308 phosphorylation. We interpreted these results as indicating that under the conditions employed to examine the effect of resveratrol on basal (non-stimulated) protein synthesis and mTORC1 signaling, AKT was not active. We concluded that inhibition of AKT was not a viable explanation for the aforementioned resveratrol effects.</p>
        <fig id="pone-0029513-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>The effect of resveratrol on AKT phosphorylation and the stability of mTORC1.</title>
            <p>H4-II-E hepatoma cells were incubated with DMSO vehicle (control), resveratrol or LY294002 for 1 h. Where noted, cells were stimulated with insulin 5 min prior to cell lysis. Cell lysates were analyzed by Western immunoblotting for total and phosphorylated AKT at Thr 308. The results of triplicate immunoblots were quantified by densitometry. Data were normalized between blots by analyzing a single control sample on all blots. The results are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2e">
        <title>Resveratrol does not disrupt mTORC1</title>
        <p>Major components of mTORC1 include mTOR itself, raptor and mLST8 <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>. Inhibition of mTORC1 signaling by rapamycin is associated with dissociation of raptor from mTOR <xref ref-type="bibr" rid="pone.0029513-Hara1">[37]</xref>, <xref ref-type="bibr" rid="pone.0029513-Kim1">[38]</xref>. Given that the upstream kinases AKT and AMPKα did not appear to be involved in resveratrol's inhibition of mTORC1, we compared its effect on mTORC1 to that of rapamycin. mTOR was immunoprecipitated from cells exposed to resveratrol and rapamycin. Raptor content in the immunoprecipitated complex was determined by immunoblotting (<xref ref-type="fig" rid="pone-0029513-g006">Figure 6</xref> and <xref ref-type="supplementary-material" rid="pone.0029513.s003">Figure S3</xref>). Consistent with previous findings <xref ref-type="bibr" rid="pone.0029513-Hara1">[37]</xref>, <xref ref-type="bibr" rid="pone.0029513-Kim1">[38]</xref>, rapamycin decreased the amount of the raptor:mTOR complex. This effect was not seen with resveratrol.</p>
        <fig id="pone-0029513-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>The effect of resveratrol and rapamycin on integrity of mTORC1.</title>
            <p>Cell lysates were analyzed by immunoprecipitation of mTOR followed by immunoblotting for raptor and mTOR. A second replicate experiment yielded similar results (<xref ref-type="supplementary-material" rid="pone.0029513.s003">Figure S3</xref>).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g006" xlink:type="simple"/>
        </fig>
        <p>Although the interpretation of immunoprecipitation kinase assays for mTOR is complicated owing to the multi-protein complexes in which mTOR resides, we considered the direct inhibition of mTOR kinase activity by resveratrol to be an important mechanism to explore. Using recombinant 4E-BP1 as a phosphate acceptor, we measure kinase activity in mTOR immunoprecipitates from cells cultured under control conditions or exposed to resveratrol. <xref ref-type="sec" rid="s2">Results</xref> (not shown) indicated no effect of resveratrol on mTOR kinase activity.</p>
      </sec>
      <sec id="s2f">
        <title>Effect of resveratrol on eIF2α phosphorylation</title>
        <p>Phosphorylation of eIF2α inhibits the ability of the eIF2 complex to deliver the charged methionyl initiator tRNA to the initiation codon, thereby downregulating translation initiation <xref ref-type="bibr" rid="pone.0029513-Wek1">[39]</xref>. eIF2α phosphorylation is mediated by multiple kinases, including GCN2. Those enzymes are not targets of mTOR. Resveratrol increased eIF2α phosphorylation at Ser 51 (<xref ref-type="fig" rid="pone-0029513-g007">Figure 7</xref>). In contrast, rapamycin had no effect while pp242 exposure was associated with a decrease in phosphorylation.</p>
        <fig id="pone-0029513-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0029513.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>The effect of resveratrol and mTOR inhibitors on eIF2α.</title>
            <p>H4-II-E hepatoma cells were incubated with DMSO vehicle (control), resveratrol, rapamycin or pp242 for 1 h. Cell lysates were analyzed by Western immunoblotting to determine the ratio of phospho∶total eIF2α. A representative immunoblot is shown below the graph. The results are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.g007" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>While limited information is available regarding the tissue uptake of resveratrol, it is known that the liver plays a key role in the metabolism of dietary polyphenols, including resveratrol. Despite the high absorption of resveratrol administered orally to humans, resveratrol bioavailability is low because it is rapidly metabolized in liver via glucuronate and sulfate conjugation <xref ref-type="bibr" rid="pone.0029513-Walle1">[40]</xref>. In fact, unmetabolized resveratrol has a relatively short half life <xref ref-type="bibr" rid="pone.0029513-Asensi1">[41]</xref>. It has been suggested, therefore, that <italic>in vitro</italic> investigations of resveratrol biological effects should focus on resveratrol conjugates <xref ref-type="bibr" rid="pone.0029513-Goldberg1">[42]</xref>. Due to the abundance of resveratrol conjugates in rat hepatocytes after incubation with resveratrol <xref ref-type="bibr" rid="pone.0029513-Yu1">[43]</xref>, we consider hepatic cells to be an advantageous model system for the investigation of resveratrol effect. Additionally, hepatic cells take up resveratrol by both passive diffusion and active transport <xref ref-type="bibr" rid="pone.0029513-Lancon1">[44]</xref>. This may account for the fact that our experiments used resveratrol at ten to twenty times lower concentrations than generally used in other types of cells, such as human embryonic kidney cells <xref ref-type="bibr" rid="pone.0029513-Armour1">[45]</xref>, cardiac myocytes <xref ref-type="bibr" rid="pone.0029513-Dolinsky1">[46]</xref>, HeLa cells <xref ref-type="bibr" rid="pone.0029513-Ghosh1">[47]</xref> and mouse embryonic fibroblasts <xref ref-type="bibr" rid="pone.0029513-Ghosh1">[47]</xref>.</p>
      <p>Hepatoma cells are also a relevant model because resveratrol has been proposed as a chemopreventative agent for human hepatocellular carcinoma <xref ref-type="bibr" rid="pone.0029513-Bishayee1">[48]</xref>, <xref ref-type="bibr" rid="pone.0029513-Bishayee2">[49]</xref> a disease in which the mTOR pathway is often constitutively activated <xref ref-type="bibr" rid="pone.0029513-Treiber1">[50]</xref>. However, the mechanisms by which resveratrol affects cancer development and/or progression remain uncertain <xref ref-type="bibr" rid="pone.0029513-Baur2">[8]</xref>, <xref ref-type="bibr" rid="pone.0029513-Athar1">[51]</xref>–<xref ref-type="bibr" rid="pone.0029513-Liu1">[53]</xref>.</p>
      <p>Inhibition of translation is known to affect numerous physiological functions, including the stress response and oncogenic signaling <xref ref-type="bibr" rid="pone.0029513-Novoa1">[54]</xref>, <xref ref-type="bibr" rid="pone.0029513-Rajasekhar1">[55]</xref> Interestingly, dietary restriction has been shown to have a dramatic effect on tumor suppression in almost every tumor tested <xref ref-type="bibr" rid="pone.0029513-Hursting1">[56]</xref> with the exception of tumors with activated PI3K <xref ref-type="bibr" rid="pone.0029513-Kalaany1">[57]</xref>. In addition, dietary restriction <xref ref-type="bibr" rid="pone.0029513-Bishop1">[9]</xref>, <xref ref-type="bibr" rid="pone.0029513-Mair1">[10]</xref> and mTOR inhibition, related conditions owing to the biological function of mTOR, increase longevity in a number of model systems. These include yeast <xref ref-type="bibr" rid="pone.0029513-Kaeberlein1">[15]</xref>, worms <xref ref-type="bibr" rid="pone.0029513-Hansen1">[11]</xref>, <xref ref-type="bibr" rid="pone.0029513-Vellai1">[13]</xref>, <xref ref-type="bibr" rid="pone.0029513-Pan1">[16]</xref> , flies <xref ref-type="bibr" rid="pone.0029513-Kapahi1">[14]</xref>, <xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>, <xref ref-type="bibr" rid="pone.0029513-Luong1">[58]</xref> and mammals <xref ref-type="bibr" rid="pone.0029513-Harrison1">[19]</xref>. Because resveratrol can extend lifespan in animals and repression of mTOR is associated with retarded aging, we hypothesized that resveratrol could modulate protein synthesis, perhaps through effects on mTOR signaling or other well-characterized mechanisms involved in the control of translation. Our data support this hypothesis.</p>
      <p>Our initial studies demonstrated that resveratrol induces a modest inhibition of global translation in H4-II-E hepatic cells. The magnitude of this effect is similar to that observed by us using rapamycin <xref ref-type="bibr" rid="pone.0029513-Jimenez1">[59]</xref>. Resveratrol-induced reduction of global protein synthesis in the H4-II-E cells was independent of any change in cell number or cell viability. Our results identified multiple signaling events that could account for this effect, including inhibition of mTOR activity (as indicated by the mTOR self-phosphorylation site), formation of the eIF4F cap-binding complex, phosphorylation of eIF4G1, and phosphorylation of eIF2α. The last of these effects was not recapitulated by rapamycin, a finding that distinguishes the signaling effects of resveratrol and from those of mTORC1-specific of general mTOR inhibition. It should be noted that our findings do not rule out other effects of resveratrol on translation initiation. In fact, eIF4A has been recently suggested as a direct target of resveratrol binding <italic>in vitro</italic> <xref ref-type="bibr" rid="pone.0029513-Lomenick1">[60]</xref>.</p>
      <p>The regulation of mTOR signaling is highly complex. It involves large, multi-protein complexes and input from an array of upstream signals <xref ref-type="bibr" rid="pone.0029513-Laplante1">[22]</xref>. Studies to date have led to the characterization of two mTOR-containing complexes, mTORC1 and mTORC2. The former is known to account for mTOR-mediated translation control and rapamycin sensitivity. Unlike rapamycin, resveratrol did not affect the binding between raptor, a component of mTORC1, and mTOR. On the other hand, we found decreased mTOR self-phosphorylation at Ser 2481. This suggested that resveratrol may directly inhibit mTOR kinase activity, a possibility that was not supported by results of immunoprecipitation kinase assays. However, resveratrol may interact with other components of the mTORC1 complex or modulate the activity of other mTOR effectors. Among these are the upstream kinases AMPK and AKT <xref ref-type="bibr" rid="pone.0029513-Pirola1">[61]</xref>. The former is especially interesting since AMPK-deficient mice have been described to be resistant to the metabolic effects of resveratrol <xref ref-type="bibr" rid="pone.0029513-Um1">[62]</xref>. However, our studies implicate neither AMPK nor AKT signaling in resveratrol-induced inhibition of mTORC1 signaling.</p>
      <p>In the case of AMPK, the basis for our results may lie in the high sensitivity of H4-II-E cells to resveratrol. We performed our studies at 5 µM, a concentration of resveratrol that did not affect cell proliferation or viability. Concentrations of resveratrol reported to activate AMPK are more than twice those used in our experiments <xref ref-type="bibr" rid="pone.0029513-Pirola1">[61]</xref>, <xref ref-type="bibr" rid="pone.0029513-Vingtdeux1">[63]</xref>–<xref ref-type="bibr" rid="pone.0029513-Puissant1">[65]</xref>. In addition, H4-II-E cells seem to be particularly resistant to AMPK activation under basal conditions, since nutrient stress (elimination of serum from culture media) was required for AICAR to activate AMPK. Similarly, the basal level of AKT phosphorylation at Thr308, the PDK1 site, was minimal in H4-II-E cells. This was most apparent when compared to cells exposed to insulin, indicating that inhibition of AKT activity is unlikely to account for any of the effects of resveratrol that we observed. An inhibitory effect of resveratrol on phosphorylation of AKT at Ser 473 has been previously observed <xref ref-type="bibr" rid="pone.0029513-Zhang1">[66]</xref>. Our results indicate that this could be due to an effect of resveratrol on mTOR signaling. However, the inhibitory effect of resveratrol on translation that we observed was seen under basal, not insulin-stimulated, conditions.</p>
      <p>A commonly cited mechanism of resveratrol action is the activation of the NAD<sup>+</sup>-dependent protein deacetylase SIRT1 <xref ref-type="bibr" rid="pone.0029513-Howitz1">[1]</xref>, <xref ref-type="bibr" rid="pone.0029513-Wood1">[2]</xref>. Given our results on AMPK and AKT signaling, the role of SIRT1 may be of particular importance. The molecular mechanism of resveratrol action through activation of SIRT1 remains to be elucidated <xref ref-type="bibr" rid="pone.0029513-Howitz1">[1]</xref>, <xref ref-type="bibr" rid="pone.0029513-Kaeberlein3">[67]</xref>, <xref ref-type="bibr" rid="pone.0029513-Kaeberlein4">[68]</xref>. In fact, recent studies suggest that resveratrol-mediated effects <italic>in vivo</italic> may be independent of a direct activation of SIRT1 <xref ref-type="bibr" rid="pone.0029513-Beher1">[69]</xref>, <xref ref-type="bibr" rid="pone.0029513-Pacholec1">[70]</xref>. More recently, SIRT1 was implicated as a regulator of mTOR signaling <xref ref-type="bibr" rid="pone.0029513-Ghosh1">[47]</xref>. In these studies, SIRT1-deficient Hela cells and mouse embryonic cells were shown to have elevated phosphorylation of S6K1 and 4EB-P1. However, these investigators found that resveratrol could decrease the phosphorylation of the S6K1 target ribosomal protein S6 in cells depleted of SIRT1, although it did so with less efficiency under these conditions <xref ref-type="bibr" rid="pone.0029513-Ghosh1">[47]</xref>. In other studies implicating S6K1 in the mechanism of resveratrol action <xref ref-type="bibr" rid="pone.0029513-Armour1">[45]</xref>, the effect was again found to be independent of SIRT1. We have performed preliminary studies showing that the inhibition of S6K1 phosphorylation by resveratrol in hepatic cells was not affected by the SIRT1 inhibitor EX527 (<xref ref-type="supplementary-material" rid="pone.0029513.s002">Figure S2A</xref>). Likewise, EX527 did not block the effect of resveratrol on the phosphorylation of 4EBP1 and mTOR (data not shown). EX527 has been used by numerous investigators as a selective inhibitor of SIRT1 deacetylase at concentrations similar to those that we employed <xref ref-type="bibr" rid="pone.0029513-Zhang1">[66]</xref>, <xref ref-type="bibr" rid="pone.0029513-Solomon1">[71]</xref>–<xref ref-type="bibr" rid="pone.0029513-Nie1">[73]</xref>. However, we were unable to validate an effect of EX527 on SIRT1 in H4-II-E cells. In an attempt to do so, we studied the expression and acetylation of several SIRT1 targets, PGC1α, FoxO1 and p53. Only p53 was detectable by Western blotting under basal conditions (<xref ref-type="supplementary-material" rid="pone.0029513.s002">Figure S2B</xref>). We detected no acetylation of this or any other SIRT1 target in the presence of EX527 despite employing a variety of conditions. Therefore, we are unable to draw any definitive conclusions regarding the efficacy of EX527 or the role of SIRT1 in the effects we observed. During the preparation of this manuscript, an inhibitory effect of resveratrol on insulin and leucine stimulated mTOR signaling was described in mouse fibroblasts <xref ref-type="bibr" rid="pone.0029513-Liu2">[74]</xref>. This effect was found to be independent of Sirt1 activation, instead involving changes in the interaction of mTOR and its inhibitor DEPTOR.</p>
      <p>The nutrient-sensing mTOR pathway has emerged as a link between nutrient availability, translation control, longevity and oncogenesis <xref ref-type="bibr" rid="pone.0029513-Hansen1">[11]</xref>, <xref ref-type="bibr" rid="pone.0029513-Vellai1">[13]</xref>–<xref ref-type="bibr" rid="pone.0029513-Bjedov1">[18]</xref>, <xref ref-type="bibr" rid="pone.0029513-Guertin2">[27]</xref>–<xref ref-type="bibr" rid="pone.0029513-Robert1">[29]</xref>, <xref ref-type="bibr" rid="pone.0029513-Luong1">[58]</xref>. Our findings identify resveratrol as a modulator of protein synthesis, translation initiation and elongation factors, and mTOR signaling. Any or all of these effects could contribute to the anti-aging and anti-carcinogenic properties of resveratrol. Furthermore, we have found that resveratrol decreases mTOR-dependent phosphorylation, although resveratrol and mTOR inhibitors show different effects on the phosphorylation of eIF2α. This increase in eIF2α phosphorylation induced by resveratrol is of particular interest given the ability of amino acid restriction to induce this same effect <xref ref-type="bibr" rid="pone.0029513-Proud1">[75]</xref>. Considered in light of the role of amino acids in modulating mTOR signaling <xref ref-type="bibr" rid="pone.0029513-Sonenberg1">[33]</xref>, we propose that resveratrol may regulate translation through mechanisms similar to those that sense reduced amino acid availability. The use of an immortalized cell line as a model system has limitations with regard to physiologic significance, so <italic>in vivo</italic> studies will be needed to more definitively address the role of resveratrol on protein translation in the liver and in other tissues and organs.</p>
    </sec>
    <sec id="s4" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title>Materials</title>
        <p>Antibodies to mTOR, phospho-mTOR, S6K1, phospho-S6K1, phospho-eIF4E-BP1, eIF4E, AMPKα, phospho-AMPKα, acetyl CoA carboxylase, phospho-acetyl CoA carboxylase, raptor, phospho-eIF2α, acetylated lysine, acetylated-p53, AKT, and phospho-AKT were purchased from Cell Signaling Technology (Danvers, MA, USA.). Antibodies to eIF4E-BP1, eIF4G1, p53, FoxO1, PGC1α, and eIF2α were purchased form Santa Cruz Biotechnology (Santa Cruz, CA, USA.). Protein A-Sepharose CL-4B and 7-methyl-GTP (7mGTP)-Sepharose 4B were purchased form GE Healthcare (Piscataway, NJ, USA.). Resveratrol was a gift from D. Sinclair (Harvard Medical School, Boston, MA, USA.). Rapamycin was purchased from LC Laboratories (Woburn, MA, USA.). pp242 was purchased from Chemdea (Ridgewood, NJ, USA.). EX527 was purchased form TOCRIS Bioscience (Ellisville, MO, USA). <sup>3</sup>H-Leu (specific activity: 100 to 150 Ci/mmol ) and <sup>14</sup>C-Leu (specific activity &gt;300 mCi/mmol) were purchased from Dupont/New England Nuclear (Boston, MA, USA). The Quant-iT PicoGreen® dsDNA Assay Kit was purchased from Invitrogen Corporation (Carlsbad, CA, USA.). Protein was quantified using the BCA Protein Assay Kit from Thermo Scientific (Rockford, IL, USA.)</p>
      </sec>
      <sec id="s4b">
        <title>Biochemical analyses</title>
        <p>H4-II-E cells <xref ref-type="bibr" rid="pone.0029513-Pitot1">[76]</xref> were cultured in Minimal Essential Medium Gibco # 4100-034 (Carlsbad, CA, USA) with 5% Fetal Bovine Serum. The composition of the media, including amino acid content, can be found at <ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com/site/us/en/home/support/Product-Technical-Resources/media_formulation.99.html" xlink:type="simple">http://www.invitrogen.com/site/us/en/home/support/Product-Technical-Resources/media_formulation.99.html</ext-link>. In particular, leucine was present at a concentration of 0.397 mM for all experiments. Resveratrol, rapamycin, pp242 and EX527 were dissolved in 100% DMSO. Control conditions used equivalent DMSO concentrations.</p>
        <p>Protein synthesis was measured as the incorporation of <sup>3</sup>H-Leu or <sup>14</sup>C-Leu into protein <xref ref-type="bibr" rid="pone.0029513-Jimenez1">[59]</xref>. Cells were plated in six well plates (2×10<sup>5</sup> per well) and allowed to attach overnight. Resveratrol and radiolabeled leucine (1 µCi/ml) were added and allowed to incubate for designated time periods prior to cell lysis. Where noted, results were normalized to DNA content, which was measured using the fluorescent Quant-iT PicoGreen® dsDNA Assay Kit with λDNA (0–500 ng/ml) as standard.</p>
        <p>For leucine uptake experiments, cells were incubated with resveratrol (5 µM) for 1 h prior to addition of <sup>3</sup>H-Leu (1 µCi/ml). Cells were lysed after 5, 10 or 15 min. Correction for non specific uptake was made by determining the amount of radiolabeled leucine retained in the extracellular space or cell surface after incubation of <sup>3</sup>H-Leu for 10 seconds. Protein degradation was also assessed, using the method of <xref ref-type="bibr" rid="pone.0029513-Ballard1">[77]</xref>, <xref ref-type="bibr" rid="pone.0029513-Montgomery1">[78]</xref>. To do so, <sup>3</sup>H-Leu was added to the cells for 24 h. Cells were washed with fresh media and incubated with resveratrol. After 6 h of incubation, cells were washed twice with cold PBS and precipitated with 10% trichloracetic acid (TCA). The percentage of protein degraded over 6 h treatment was calculated as 100D/(D+E+F) where D is the total cpm in the TCA precipitated fraction, E is the total cpm in the TCA non precipitated fraction, and F is the total cpm in the resveratrol media and PBS washes.</p>
        <p>Western immunoblotting was carried out as previously described <xref ref-type="bibr" rid="pone.0029513-Jimenez1">[59]</xref>, <xref ref-type="bibr" rid="pone.0029513-Anand1">[79]</xref>. For 7mGTP cap-binding studies, Western immunoblotting and mTOR immunoprecipitation, cells (2×10<sup>6</sup> per well) were allowed to attach overnight to 10 cm plates. Resveratrol (5 µM), rapamycin (100 nM) <xref ref-type="bibr" rid="pone.0029513-Hursting1">[56]</xref>, pp242 (100 nM) <xref ref-type="bibr" rid="pone.0029513-Feldman1">[80]</xref> and EX527 (1 µM or 5 µM) were added to cells for 1 h. In experiments where cells were serum deprived, cells were transferred to serum-free media and exposed to resveratrol (5 µM) or AICAR (0.5 mM) for 1 h. In experiments where cells were stimulated with insulin, cells were incubated with resveratrol (5 µM) or LY294002 (10 µM) for 1 h and exposed to insulin (100 nM) for 5 min prior cell lyses.</p>
        <p>For 7mGTP cap-binding analysis, cell lysates were prepared and analyzed as previously described <xref ref-type="bibr" rid="pone.0029513-Feldman1">[80]</xref>. For mTOR immunoprecipitation, cells were lysed in 0.3% Chaps buffer <xref ref-type="bibr" rid="pone.0029513-Kim1">[38]</xref> and sonicated 2 times for 10 seconds. After pre-clearing with protein A-Sepharose CL-4B, 400 µg of cell lysate protein was incubated overnight with mTOR antibody. A 1∶1 suspension of protein A-Sepharose CL-4B (50 µl) in 0.3% Chaps buffer was added to the sample and incubated for 3 h at 4°C. Immunoprecipitates were washed with 0.3% Chaps buffer four times, and samples were resolved and analyzed by immunoblotting.</p>
      </sec>
      <sec id="s4c">
        <title>Statistical analyses</title>
        <p>Except where noted, data are shown as the mean and standard deviation. Two-way comparisons were performed using the unpaired t-test. Analysis of variance with a Tukey post hoc test was used in cases of multiple comparisons. Differences were considered significant at p&lt;0.05. Experiments were independently repeated at least twice with three biological replicates each time.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pone.0029513.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.s001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p><bold>The effect of resveratrol on leucine uptake and protein degradation.</bold> <italic>Panel A:</italic> Leucine uptake. H4-II-E hepatoma cells were incubated with resveratrol for 1 h prior to addition of <sup>3</sup>H-Leu. Cells were lysed after 5, 10 or 15 min. Correction for non specific uptake was made by determining the amount of radiolabeled leucine retained in the extracellular space or cell surface after incubation of <sup>3</sup>H-Leu for 10 seconds. P = 0.119 at 15 minutes. <italic>Panel B:</italic> Protein degradation was assessed by measuring the uptake and subsequent release of <sup>3</sup>H-Leu. <sup>3</sup>H-Leu was added to the cells for 24 h. Cells were washed with fresh media and incubated with resveratrol or vehicle control. After 6 h of incubation, cells were washed twice with cold PBS and precipitated with 10% trichloracetic acid (TCA). The percentage of protein degraded over 6 h treatment was calculated as 100D/(D+E+F) where D is the total cpm in the TCA precipitated fraction, E is the total cpm in the TCA non precipitated fraction, and F is the total cpm in the resveratrol media and PBS washes. The results are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0029513.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.s002" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p><bold>The effect of EX527 on the effect of resveratrol.</bold> <italic>Panel A</italic>: H4-II-E hepatoma cells were incubated for 1 h with DMSO vehicle or resveratrol (5 µM) in the presence of 0, 1 or 5 µM EX527. Cell lysates were analyzed by immunoblotting for total and phosphorylated S6K1. The Western immunoblots were quantified by densitometry to determine the ratio of phospho∶total S6K1. A representative immunoblot is shown below the graph. The results are shown as the mean ± SD. *P&lt;0.05 versus control as determined by ANOVA. <italic>Panel B</italic>: The cell lysates prepared for the experiment shown in <italic>Panel A</italic> were analyzed by immunoprecipitation of p53 followed by Western immunoblotting for acetylated and total p53.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0029513.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0029513.s003" xlink:type="simple">
        <label>Figure S3</label>
        <caption>
          <p><bold>Independent repetition of the effect of resveratrol and rapamycin on integrity of mTORC1.</bold> Cell lysates were analyzed by immunoprecipitation of mTOR followed by immunoblotting for raptor and mTOR.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank members of the Gruppuso and Tatar laboratories for advice and discussion.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0029513-Howitz1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Howitz</surname><given-names>KT</given-names></name><name name-style="western"><surname>Bitterman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>HY</given-names></name><name name-style="western"><surname>Lamming</surname><given-names>DW</given-names></name><name name-style="western"><surname>Lavu</surname><given-names>S</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.</article-title>             <source>Nature</source>             <volume>425</volume>             <fpage>191</fpage>             <lpage>196</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Wood1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>JG</given-names></name><name name-style="western"><surname>Rogina</surname><given-names>B</given-names></name><name name-style="western"><surname>Lavu</surname><given-names>S</given-names></name><name name-style="western"><surname>Howitz</surname><given-names>K</given-names></name><name name-style="western"><surname>Helfand</surname><given-names>SL</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Sirtuin activators mimic caloric restriction and delay ageing in metazoans.</article-title>             <source>Nature</source>             <volume>430</volume>             <fpage>686</fpage>             <lpage>689</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Valenzano1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Valenzano</surname><given-names>DR</given-names></name><name name-style="western"><surname>Terzibasi</surname><given-names>E</given-names></name><name name-style="western"><surname>Genade</surname><given-names>T</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>A</given-names></name><name name-style="western"><surname>Domenici</surname><given-names>L</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate.</article-title>             <source>Curr Biol</source>             <volume>16</volume>             <fpage>296</fpage>             <lpage>300</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Jang1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Udeani</surname><given-names>GO</given-names></name><name name-style="western"><surname>Slowing</surname><given-names>KV</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>CF</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.</article-title>             <source>Science</source>             <volume>275</volume>             <fpage>218</fpage>             <lpage>220</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Parker1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>JA</given-names></name><name name-style="western"><surname>Arango</surname><given-names>M</given-names></name><name name-style="western"><surname>Abderrahmane</surname><given-names>S</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>E</given-names></name><name name-style="western"><surname>Tourette</surname><given-names>C</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons.</article-title>             <source>Nat Genet</source>             <volume>37</volume>             <fpage>349</fpage>             <lpage>350</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Anekonda1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Anekonda</surname><given-names>TS</given-names></name></person-group>             <year>2006</year>             <article-title>Resveratrol–a boon for treating Alzheimer's disease?</article-title>             <source>Brain Res Rev</source>             <volume>52</volume>             <fpage>316</fpage>             <lpage>326</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Baur1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Baur</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Price</surname><given-names>NL</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>HA</given-names></name><name name-style="western"><surname>Lerin</surname><given-names>C</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Resveratrol improves health and survival of mice on a high-calorie diet.</article-title>             <source>Nature</source>             <volume>444</volume>             <fpage>337</fpage>             <lpage>342</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Baur2">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Baur</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>DA</given-names></name></person-group>             <year>2006</year>             <article-title>Therapeutic potential of resveratrol: the in vivo evidence.</article-title>             <source>Nat Rev Drug Discov</source>             <volume>5</volume>             <fpage>493</fpage>             <lpage>506</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Bishop1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>NA</given-names></name><name name-style="western"><surname>Guarente</surname><given-names>L</given-names></name></person-group>             <year>2007</year>             <article-title>Genetic links between diet and lifespan: shared mechanisms from yeast to humans.</article-title>             <source>Nat Rev Genet</source>             <volume>8</volume>             <fpage>835</fpage>             <lpage>844</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Mair1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mair</surname><given-names>W</given-names></name><name name-style="western"><surname>Dillin</surname><given-names>A</given-names></name></person-group>             <year>2008</year>             <article-title>Aging and survival: the genetics of life span extension by dietary restriction.</article-title>             <source>Annu Rev Biochem</source>             <volume>77</volume>             <fpage>727</fpage>             <lpage>754</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Hansen1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>M</given-names></name><name name-style="western"><surname>Taubert</surname><given-names>S</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>D</given-names></name><name name-style="western"><surname>Libina</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans.</article-title>             <source>Aging Cell</source>             <volume>6</volume>             <fpage>95</fpage>             <lpage>110</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Zid1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zid</surname><given-names>BM</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>AN</given-names></name><name name-style="western"><surname>Katewa</surname><given-names>SD</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kolipinski</surname><given-names>MC</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila.</article-title>             <source>Cell</source>             <volume>139</volume>             <fpage>149</fpage>             <lpage>160</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Vellai1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vellai</surname><given-names>T</given-names></name><name name-style="western"><surname>Takacs-Vellai</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>AL</given-names></name><name name-style="western"><surname>Orosz</surname><given-names>L</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Genetics: influence of TOR kinase on lifespan in C. elegans.</article-title>             <source>Nature</source>             <volume>426</volume>             <fpage>620</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kapahi1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kapahi</surname><given-names>P</given-names></name><name name-style="western"><surname>Zid</surname><given-names>B</given-names></name></person-group>             <year>2004</year>             <article-title>TOR pathway: linking nutrient sensing to life span.</article-title>             <source>Sci Aging Knowledge Environ</source>             <volume>2004</volume>             <fpage>PE34</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kaeberlein1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kaeberlein</surname><given-names>M</given-names></name><name name-style="western"><surname>Burtner</surname><given-names>CR</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>BK</given-names></name></person-group>             <year>2007</year>             <article-title>Recent developments in yeast aging.</article-title>             <source>PLoS Genet</source>             <volume>3</volume>             <fpage>e84</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Pan1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>KZ</given-names></name><name name-style="western"><surname>Palter</surname><given-names>JE</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>AN</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans.</article-title>             <source>Aging Cell</source>             <volume>6</volume>             <fpage>111</fpage>             <lpage>119</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Selman1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Selman</surname><given-names>C</given-names></name><name name-style="western"><surname>Tullet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wieser</surname><given-names>D</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>E</given-names></name><name name-style="western"><surname>Lingard</surname><given-names>SJ</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.</article-title>             <source>Science</source>             <volume>326</volume>             <fpage>140</fpage>             <lpage>144</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Bjedov1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bjedov</surname><given-names>I</given-names></name><name name-style="western"><surname>Toivonen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>F</given-names></name><name name-style="western"><surname>Slack</surname><given-names>C</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>J</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster.</article-title>             <source>Cell Metab</source>             <volume>11</volume>             <fpage>35</fpage>             <lpage>46</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Harrison1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>DE</given-names></name><name name-style="western"><surname>Strong</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>ZD</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Astle</surname><given-names>CM</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.</article-title>             <source>Nature</source>             <volume>460</volume>             <fpage>392</fpage>             <lpage>395</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Ma1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>XM</given-names></name><name name-style="western"><surname>Blenis</surname><given-names>J</given-names></name></person-group>             <year>2009</year>             <article-title>Molecular mechanisms of mTOR-mediated translational control.</article-title>             <source>Nat Rev Mol Cell Biol</source>             <volume>10</volume>             <fpage>307</fpage>             <lpage>318</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Richter1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></name></person-group>             <year>2005</year>             <article-title>Regulation of cap-dependent translation by eIF4E inhibitory proteins.</article-title>             <source>Nature</source>             <volume>433</volume>             <fpage>477</fpage>             <lpage>480</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Laplante1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Laplante</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name></person-group>             <year>2009</year>             <article-title>mTOR signaling at a glance.</article-title>             <source>J Cell Sci</source>             <volume>122</volume>             <fpage>3589</fpage>             <lpage>3594</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Gwinn1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gwinn</surname><given-names>DM</given-names></name><name name-style="western"><surname>Shackelford</surname><given-names>DB</given-names></name><name name-style="western"><surname>Egan</surname><given-names>DF</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mery</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>AMPK phosphorylation of raptor mediates a metabolic checkpoint.</article-title>             <source>Mol Cell</source>             <volume>30</volume>             <fpage>214</fpage>             <lpage>226</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Anisimov1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Anisimov</surname><given-names>VN</given-names></name><name name-style="western"><surname>Berstein</surname><given-names>LM</given-names></name><name name-style="western"><surname>Egormin</surname><given-names>PA</given-names></name><name name-style="western"><surname>Piskunova</surname><given-names>TS</given-names></name><name name-style="western"><surname>Popovich</surname><given-names>IG</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Metformin slows down aging and extends life span of female SHR mice.</article-title>             <source>Cell Cycle</source>             <volume>7</volume>             <fpage>2769</fpage>             <lpage>2773</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Anisimov2">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Anisimov</surname><given-names>VN</given-names></name><name name-style="western"><surname>Egormin</surname><given-names>PA</given-names></name><name name-style="western"><surname>Piskunova</surname><given-names>TS</given-names></name><name name-style="western"><surname>Popovich</surname><given-names>IG</given-names></name><name name-style="western"><surname>Tyndyk</surname><given-names>ML</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.</article-title>             <source>Cell Cycle</source>             <volume>9</volume>             <fpage>188</fpage>             <lpage>197</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Guertin1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guertin</surname><given-names>DA</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name></person-group>             <year>2009</year>             <article-title>The pharmacology of mTOR inhibition.</article-title>             <source>Sci Signal</source>             <volume>2</volume>             <fpage>pe24</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Guertin2">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guertin</surname><given-names>DA</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name></person-group>             <year>2007</year>             <article-title>Defining the role of mTOR in cancer.</article-title>             <source>Cancer Cell</source>             <volume>12</volume>             <fpage>9</fpage>             <lpage>22</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Efeyan1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Efeyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name></person-group>             <year>2009</year>             <article-title>mTOR and cancer: many loops in one pathway.</article-title>             <source>Curr Opin Cell Biol</source>          </element-citation>
      </ref>
      <ref id="pone.0029513-Robert1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>F</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>J</given-names></name></person-group>             <year>2009</year>             <article-title>Translation initiation: a critical signalling node in cancer.</article-title>             <source>Expert Opin Ther Targets</source>             <volume>13</volume>             <fpage>1279</fpage>             <lpage>1293</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Wei1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Fabrizio</surname><given-names>P</given-names></name><name name-style="western"><surname>Madia</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension.</article-title>             <source>PLoS Genet</source>             <volume>5</volume>             <fpage>e1000467</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kaeberlein2">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kaeberlein</surname><given-names>M</given-names></name></person-group>             <year>2010</year>             <article-title>Resveratrol and rapamycin: are they anti-aging drugs?</article-title>             <source>Bioessays</source>             <volume>32</volume>             <fpage>96</fpage>             <lpage>99</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Delmas1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Delmas</surname><given-names>D</given-names></name><name name-style="western"><surname>Jannin</surname><given-names>B</given-names></name><name name-style="western"><surname>Cherkaoui Malki</surname><given-names>M</given-names></name><name name-style="western"><surname>Latruffe</surname><given-names>N</given-names></name></person-group>             <year>2000</year>             <article-title>Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines.</article-title>             <source>Oncol Rep</source>             <volume>7</volume>             <fpage>847</fpage>             <lpage>852</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Sonenberg1">
        <label>33</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></name><name name-style="western"><surname>Hershey</surname><given-names>JWB</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>MB</given-names></name></person-group>             <year>2000</year>             <comment>Translational control of gene expression</comment>          </element-citation>
      </ref>
      <ref id="pone.0029513-Raught1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Raught</surname><given-names>B</given-names></name><name name-style="western"><surname>Gingras</surname><given-names>AC</given-names></name><name name-style="western"><surname>Gygi</surname><given-names>SP</given-names></name><name name-style="western"><surname>Imataka</surname><given-names>H</given-names></name><name name-style="western"><surname>Morino</surname><given-names>S</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.</article-title>             <source>Embo J</source>             <volume>19</volume>             <fpage>434</fpage>             <lpage>444</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Corton1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Corton</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>JG</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DG</given-names></name></person-group>             <year>1995</year>             <article-title>5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?</article-title>             <source>Eur J Biochem</source>             <volume>229</volume>             <fpage>558</fpage>             <lpage>565</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Vlahos1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vlahos</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Matter</surname><given-names>WF</given-names></name><name name-style="western"><surname>Hui</surname><given-names>KY</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RF</given-names></name></person-group>             <year>1994</year>             <article-title>A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).</article-title>             <source>J Biol Chem</source>             <volume>269</volume>             <fpage>5241</fpage>             <lpage>5248</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Hara1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>K</given-names></name><name name-style="western"><surname>Maruki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>K</given-names></name><name name-style="western"><surname>Oshiro</surname><given-names>N</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.</article-title>             <source>Cell</source>             <volume>110</volume>             <fpage>177</fpage>             <lpage>189</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kim1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sarbassov</surname><given-names>DD</given-names></name><name name-style="western"><surname>Ali</surname><given-names>SM</given-names></name><name name-style="western"><surname>King</surname><given-names>JE</given-names></name><name name-style="western"><surname>Latek</surname><given-names>RR</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.</article-title>             <source>Cell</source>             <volume>110</volume>             <fpage>163</fpage>             <lpage>175</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Wek1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wek</surname><given-names>RC</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>TG</given-names></name></person-group>             <year>2006</year>             <article-title>Coping with stress: eIF2 kinases and translational control.</article-title>             <source>Biochem Soc Trans</source>             <volume>34</volume>             <fpage>7</fpage>             <lpage>11</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Walle1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Walle</surname><given-names>T</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>F</given-names></name><name name-style="western"><surname>DeLegge</surname><given-names>MH</given-names></name><name name-style="western"><surname>Oatis</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Walle</surname><given-names>UK</given-names></name></person-group>             <year>2004</year>             <article-title>High absorption but very low bioavailability of oral resveratrol in humans.</article-title>             <source>Drug Metab Dispos</source>             <volume>32</volume>             <fpage>1377</fpage>             <lpage>1382</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Asensi1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Asensi</surname><given-names>M</given-names></name><name name-style="western"><surname>Medina</surname><given-names>I</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>A</given-names></name><name name-style="western"><surname>Carretero</surname><given-names>J</given-names></name><name name-style="western"><surname>Bano</surname><given-names>MC</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Inhibition of cancer growth by resveratrol is related to its low bioavailability.</article-title>             <source>Free Radic Biol Med</source>             <volume>33</volume>             <fpage>387</fpage>             <lpage>398</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Goldberg1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>DM</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Soleas</surname><given-names>GJ</given-names></name></person-group>             <year>2003</year>             <article-title>Absorption of three wine-related polyphenols in three different matrices by healthy subjects.</article-title>             <source>Clin Biochem</source>             <volume>36</volume>             <fpage>79</fpage>             <lpage>87</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Yu1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Shin</surname><given-names>YG</given-names></name><name name-style="western"><surname>Chow</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kosmeder</surname><given-names>JW</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Human, rat, and mouse metabolism of resveratrol.</article-title>             <source>Pharm Res</source>             <volume>19</volume>             <fpage>1907</fpage>             <lpage>1914</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Lancon1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lancon</surname><given-names>A</given-names></name><name name-style="western"><surname>Delmas</surname><given-names>D</given-names></name><name name-style="western"><surname>Osman</surname><given-names>H</given-names></name><name name-style="western"><surname>Thenot</surname><given-names>JP</given-names></name><name name-style="western"><surname>Jannin</surname><given-names>B</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>316</volume>             <fpage>1132</fpage>             <lpage>1137</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Armour1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Armour</surname><given-names>SM</given-names></name><name name-style="western"><surname>Baur</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>SN</given-names></name><name name-style="western"><surname>Land-Bracha</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SM</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Inhibition of Mammalian S6 Kinase by Resveratrol Suppresses Autophagy.</article-title>             <source>AGING</source>             <volume>1</volume>             <fpage>515</fpage>             <lpage>528</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Dolinsky1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dolinsky</surname><given-names>VW</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AY</given-names></name><name name-style="western"><surname>Robillard Frayne</surname><given-names>I</given-names></name><name name-style="western"><surname>Light</surname><given-names>PE</given-names></name><name name-style="western"><surname>Des Rosiers</surname><given-names>C</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.</article-title>             <source>Circulation</source>             <volume>119</volume>             <fpage>1643</fpage>             <lpage>1652</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Ghosh1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>HS</given-names></name><name name-style="western"><surname>McBurney</surname><given-names>M</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>PD</given-names></name></person-group>             <year>2010</year>             <article-title>SIRT1 negatively regulates the mammalian target of rapamycin.</article-title>             <source>PLoS One</source>             <volume>5</volume>             <fpage>e9199</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Bishayee1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bishayee</surname><given-names>A</given-names></name></person-group>             <year>2009</year>             <article-title>Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.</article-title>             <source>Cancer Prev Res (Phila)</source>             <volume>2</volume>             <fpage>409</fpage>             <lpage>418</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Bishayee2">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bishayee</surname><given-names>A</given-names></name><name name-style="western"><surname>Dhir</surname><given-names>N</given-names></name></person-group>             <year>2009</year>             <article-title>Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis.</article-title>             <source>Chem Biol Interact</source>             <volume>179</volume>             <fpage>131</fpage>             <lpage>144</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Treiber1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Treiber</surname><given-names>G</given-names></name></person-group>             <year>2009</year>             <article-title>mTOR inhibitors for hepatocellular cancer: a forward-moving target.</article-title>             <source>Expert Rev Anticancer Ther</source>             <volume>9</volume>             <fpage>247</fpage>             <lpage>261</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Athar1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Athar</surname><given-names>M</given-names></name><name name-style="western"><surname>Back</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kopelovich</surname><given-names>L</given-names></name><name name-style="western"><surname>Bickers</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>AL</given-names></name></person-group>             <year>2009</year>             <article-title>Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms.</article-title>             <source>Arch Biochem Biophys</source>             <volume>486</volume>             <fpage>95</fpage>             <lpage>102</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Campisi1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Campisi</surname><given-names>J</given-names></name><name name-style="western"><surname>Yaswen</surname><given-names>P</given-names></name></person-group>             <year>2009</year>             <article-title>Aging and cancer cell biology, 2009.</article-title>             <source>Aging Cell</source>             <volume>8</volume>             <fpage>221</fpage>             <lpage>225</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Liu1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>PY</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>GM</given-names></name></person-group>             <year>2009</year>             <article-title>The critical role of the class III histone deacetylase SIRT1 in cancer.</article-title>             <source>Cancer Res</source>             <volume>69</volume>             <fpage>1702</fpage>             <lpage>1705</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Novoa1">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Novoa</surname><given-names>I</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name><name name-style="western"><surname>Jungreis</surname><given-names>R</given-names></name><name name-style="western"><surname>Harding</surname><given-names>HP</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Stress-induced gene expression requires programmed recovery from translational repression.</article-title>             <source>EMBO J</source>             <volume>22</volume>             <fpage>1180</fpage>             <lpage>1187</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Rajasekhar1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rajasekhar</surname><given-names>VK</given-names></name><name name-style="western"><surname>Viale</surname><given-names>A</given-names></name><name name-style="western"><surname>Socci</surname><given-names>ND</given-names></name><name name-style="western"><surname>Wiedmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes.</article-title>             <source>Mol Cell</source>             <volume>12</volume>             <fpage>889</fpage>             <lpage>901</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Hursting1">
        <label>56</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hursting</surname><given-names>SD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lashinger</surname><given-names>LM</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>AE</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>SN</given-names></name></person-group>             <year>2010</year>             <article-title>Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research.</article-title>             <source>Carcinogenesis</source>             <volume>31</volume>             <fpage>83</fpage>             <lpage>89</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kalaany1">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kalaany</surname><given-names>NY</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name></person-group>             <year>2009</year>             <article-title>Tumours with PI3K activation are resistant to dietary restriction.</article-title>             <source>Nature</source>             <volume>458</volume>             <fpage>725</fpage>             <lpage>731</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Luong1">
        <label>58</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Luong</surname><given-names>N</given-names></name><name name-style="western"><surname>Davies</surname><given-names>CR</given-names></name><name name-style="western"><surname>Wessells</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Graham</surname><given-names>SM</given-names></name><name name-style="western"><surname>King</surname><given-names>MT</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity.</article-title>             <source>Cell Metab</source>             <volume>4</volume>             <fpage>133</fpage>             <lpage>142</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Jimenez1">
        <label>59</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jimenez</surname><given-names>RH</given-names></name><name name-style="western"><surname>Boylan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Francesconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>G</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e7373</fpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Lomenick1">
        <label>60</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lomenick</surname><given-names>B</given-names></name><name name-style="western"><surname>Hao</surname><given-names>R</given-names></name><name name-style="western"><surname>Jonai</surname><given-names>N</given-names></name><name name-style="western"><surname>Chin</surname><given-names>RM</given-names></name><name name-style="western"><surname>Aghajan</surname><given-names>M</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Target identification using drug affinity responsive target stability (DARTS).</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>106</volume>             <fpage>21984</fpage>             <lpage>21989</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Pirola1">
        <label>61</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pirola</surname><given-names>L</given-names></name><name name-style="western"><surname>Frojdo</surname><given-names>S</given-names></name></person-group>             <year>2008</year>             <article-title>Resveratrol: one molecule, many targets.</article-title>             <source>IUBMB Life</source>             <volume>60</volume>             <fpage>323</fpage>             <lpage>332</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Um1">
        <label>62</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Um</surname><given-names>JH</given-names></name><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Foretz</surname><given-names>M</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol.</article-title>             <source>Diabetes</source>             <volume>59</volume>             <fpage>554</fpage>             <lpage>563</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Vingtdeux1">
        <label>63</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vingtdeux</surname><given-names>V</given-names></name><name name-style="western"><surname>Giliberto</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Chandakkar</surname><given-names>P</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.</article-title>             <source>J Biol Chem</source>             <volume>285</volume>             <fpage>9100</fpage>             <lpage>9113</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Lin1">
        <label>64</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lin</surname><given-names>VC</given-names></name><name name-style="western"><surname>Rau</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>DH</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation.</article-title>             <source>J Agric Food Chem</source>             <volume>58</volume>             <fpage>1584</fpage>             <lpage>1592</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Puissant1">
        <label>65</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Puissant</surname><given-names>A</given-names></name><name name-style="western"><surname>Robert</surname><given-names>G</given-names></name><name name-style="western"><surname>Fenouille</surname><given-names>N</given-names></name><name name-style="western"><surname>Luciano</surname><given-names>F</given-names></name><name name-style="western"><surname>Cassuto</surname><given-names>JP</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.</article-title>             <source>Cancer Res</source>             <volume>70</volume>             <fpage>1042</fpage>             <lpage>1052</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Zhang1">
        <label>66</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group>             <year>2006</year>             <article-title>Resveratrol inhibits insulin responses in a SirT1-independent pathway.</article-title>             <source>Biochem J</source>             <volume>397</volume>             <fpage>519</fpage>             <lpage>527</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kaeberlein3">
        <label>67</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kaeberlein</surname><given-names>M</given-names></name><name name-style="western"><surname>McDonagh</surname><given-names>T</given-names></name><name name-style="western"><surname>Heltweg</surname><given-names>B</given-names></name><name name-style="western"><surname>Hixon</surname><given-names>J</given-names></name><name name-style="western"><surname>Westman</surname><given-names>EA</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Substrate-specific activation of sirtuins by resveratrol.</article-title>             <source>J Biol Chem</source>             <volume>280</volume>             <fpage>17038</fpage>             <lpage>17045</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kaeberlein4">
        <label>68</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kaeberlein</surname><given-names>M</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>BK</given-names></name></person-group>             <year>2007</year>             <article-title>Does resveratrol activate yeast Sir2 in vivo?</article-title>             <source>Aging Cell</source>             <volume>6</volume>             <fpage>415</fpage>             <lpage>416</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Beher1">
        <label>69</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Beher</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cumine</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Lu</surname><given-names>SC</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Resveratrol is not a direct activator of SIRT1 enzyme activity.</article-title>             <source>Chem Biol Drug Des</source>             <volume>74</volume>             <fpage>619</fpage>             <lpage>624</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Pacholec1">
        <label>70</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pacholec</surname><given-names>M</given-names></name><name name-style="western"><surname>Bleasdale</surname><given-names>JE</given-names></name><name name-style="western"><surname>Chrunyk</surname><given-names>B</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>D</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.</article-title>             <source>J Biol Chem</source>             <volume>285</volume>             <fpage>8340</fpage>             <lpage>8351</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Solomon1">
        <label>71</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pasupuleti</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>McDonagh</surname><given-names>T</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>R</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.</article-title>             <source>Mol Cell Biol</source>             <volume>26</volume>             <fpage>28</fpage>             <lpage>38</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Kabra1">
        <label>72</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kabra</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.</article-title>             <source>J Biol Chem</source>             <volume>284</volume>             <fpage>18210</fpage>             <lpage>18217</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Nie1">
        <label>73</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Erion</surname><given-names>DM</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>GI</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>STAT3 inhibition of gluconeogenesis is downregulated by SirT1.</article-title>             <source>Nat Cell Biol</source>             <volume>11</volume>             <fpage>492</fpage>             <lpage>500</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Liu2">
        <label>74</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RH</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR.</article-title>             <source>J Biol Chem</source>             <volume>285</volume>             <fpage>36387</fpage>             <lpage>36394</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Proud1">
        <label>75</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>CG</given-names></name></person-group>             <year>2005</year>             <article-title>eIF2 and the control of cell physiology.</article-title>             <source>Semin Cell Dev Biol</source>             <volume>16</volume>             <fpage>3</fpage>             <lpage>12</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Pitot1">
        <label>76</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pitot</surname><given-names>HC</given-names></name><name name-style="western"><surname>Peraino</surname><given-names>C</given-names></name><name name-style="western"><surname>Morse</surname><given-names>PA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Potter</surname><given-names>VR</given-names></name></person-group>             <year>1964</year>             <article-title>Hepatomas in Tissue Culture Compared with Adapting Liver in Vivo.</article-title>             <source>Natl Cancer Inst Monogr</source>             <volume>13</volume>             <fpage>229</fpage>             <lpage>245</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Ballard1">
        <label>77</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ballard</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Read</surname><given-names>LC</given-names></name><name name-style="western"><surname>Francis</surname><given-names>GL</given-names></name><name name-style="western"><surname>Bagley</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>JC</given-names></name></person-group>             <year>1986</year>             <article-title>Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts.</article-title>             <source>Biochem J</source>             <volume>233</volume>             <fpage>223</fpage>             <lpage>230</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Montgomery1">
        <label>78</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>JL</given-names></name><name name-style="western"><surname>Harper</surname><given-names>WM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Miller</surname><given-names>MF</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>KJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Blanton</surname><given-names>JR</given-names><suffix>Jr</suffix></name></person-group>             <year>2002</year>             <article-title>Measurement of protein synthesis and degradation in C2C2) myoblasts using extracts of muscle from hormone treated bovine.</article-title>             <source>Methods Cell Sci</source>             <volume>24</volume>             <fpage>123</fpage>             <lpage>129</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Anand1">
        <label>79</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>P</given-names></name><name name-style="western"><surname>Gruppuso</surname><given-names>PA</given-names></name></person-group>             <year>2006</year>             <article-title>Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation.</article-title>             <source>J Nutr</source>             <volume>136</volume>             <fpage>27</fpage>             <lpage>33</lpage>          </element-citation>
      </ref>
      <ref id="pone.0029513-Feldman1">
        <label>80</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Apsel</surname><given-names>B</given-names></name><name name-style="western"><surname>Uotila</surname><given-names>A</given-names></name><name name-style="western"><surname>Loewith</surname><given-names>R</given-names></name><name name-style="western"><surname>Knight</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Ruggero</surname><given-names>D</given-names></name><name name-style="western"><surname>Shokat</surname><given-names>KM</given-names></name></person-group>             <year>2009</year>             <article-title>Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.</article-title>             <source>PLoS Biol</source>             <volume>7</volume>             <fpage>e38</fpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>